Seres Therapeutics (NASDAQ:MCRB) Downgraded by Wall Street Zen to Strong Sell

Wall Street Zen cut shares of Seres Therapeutics (NASDAQ:MCRB) from a hold rating to a strong sell rating in a report issued on Saturday morning,Wall Street Zen reports.

Separately, Weiss Ratings downgraded shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Seres Therapeutics presently has an average rating of “Hold” and an average target price of $17.00.

Seres Therapeutics Stock Performance

MCRB opened at $1.98 on Friday. Seres Therapeutics has a one year low of $1.67 and a one year high of $29.98. The stock has a market capitalization of $20.19 million, a PE ratio of -0.40 and a beta of 0.44. The business’s 50 day moving average price is $3.34 and its 200 day moving average price is $6.85.

Seres Therapeutics (NASDAQ:MCRB) last issued its quarterly earnings data on Wednesday, November 4th. The biotechnology company reported ($1.63) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.00) by ($0.63). The firm had revenue of $0.59 million during the quarter, compared to analyst estimates of $6.35 million. Seres Therapeutics had a negative net margin of 2,209.55% and a negative return on equity of 194.42%. As a group, equities research analysts forecast that Seres Therapeutics will post -6.78 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Seres Therapeutics

A hedge fund recently bought a new stake in Seres Therapeutics stock. Integrated Wealth Concepts LLC acquired a new position in Seres Therapeutics, Inc. (NASDAQ:MCRB) during the 2nd quarter, according to its most recent filing with the SEC. The fund acquired 4,000 shares of the biotechnology company’s stock, valued at approximately $32,000. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics, Inc is a biotechnology company focused on developing live biotherapeutic products designed to restore the function of the human microbiome. The company’s platform uses defined communities of microorganisms rather than conventional fecal material to address diseases associated with microbiome disruption.

Seres’ lead product, VOWST (fecal microbiota spores, live-brpk), was approved by the U.S. Food and Drug Administration in 2023 to prevent the recurrence of Clostridioides difficile infection in adults following antibacterial treatment.